CPA
PLSE icon

Capital Performance Advisors’s Pulse Biosciences PLSE Stock Holding History

Capital Performance Advisors’s Portfolio PLSE Stock Details PLSE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-4
Closed -$70 – 1996
2024
Q3 		$70 Buy
+4
New +$68 ﹤0.01% 2756

Other funds holding PLSE

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GAM
Griffin Asset Management New York $887M AUM 21.42% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Capital Performance Advisors's PLSE Position: Q4 2024 in Review

Capital Performance Advisors sold out of Pulse Biosciences (PLSE) in Q4 2024, closing a stake of 4 shares — an estimated $70 sold.

Capital Performance Advisors first reported a position in PLSE in Q3 2024 and held it in 1 quarter. The position peaked at $70 in Q3 2024. 73 funds tracked by Wall St. Rank hold PLSE as of Q4 2024.

  • Capital Performance Advisors reported no remaining Pulse Biosciences position as of Q4 2024 after selling out during the quarter.
  • Capital Performance Advisors sold 4 Pulse Biosciences shares in Q4 2024, an estimated $70.
  • Capital Performance Advisors first reported a position in Pulse Biosciences in Q3 2024 and held it in 1 quarter.
  • Capital Performance Advisors's Pulse Biosciences position peaked at $70 in Q3 2024.
  • 73 funds tracked by Wall St. Rank held Pulse Biosciences as of Q4 2024.

Based on Capital Performance Advisors's 13F filing for Q4 2024, filed 31 Jan 2025.